Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605285 | 0.85 | TDP1 (0.57) | TDP1TSHRNFE2L2KEAP1LTA4H | |
| SCHEMBL10442255 | 0.84 | CA12 (0.47) | NFE2L2KEAP1LTA4HHRH3ESR1 | |
| SCHEMBL6802602 | 0.84 | LTA4H (0.61) | TDP1TSHRNFE2L2KEAP1LTA4H | |
| SCHEMBL12089201 | 0.84 | KCNH2 (0.56) | TSHRNFE2L2KEAP1LTA4HHRH3 | |
| SCHEMBL12744959 | 0.81 | LTA4H (0.58) | TSHRLTA4HALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL56571 | 0.81 | KEAP1 (0.67) | TDP1TSHRNFE2L2KEAP1LTA4H | |
| SCHEMBL2022333 | 0.81 | KCNH2 (0.56) | TDP1TSHRNFE2L2KEAP1LTA4H | |
| SCHEMBL15834052 | 0.81 | HRH3 (0.50) | TSHRNFE2L2KEAP1LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL3570082 | 0.79 | KEAP1 (0.65) | TDP1TSHRNFE2L2KEAP1LTA4H | |
| SCHEMBL12156398 | 0.79 | TDP1 (0.53) | TDP1TSHRNFE2L2KEAP1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | TDP1 2230/4885TSHR 1156/4885NFE2L2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.